SynektikNarrow moat

SNT — overall economic moat

Investment snapshot
Narrow moat→ Holding steadyConfidenceMediumValuationFair
Strongest advantageThe exclusive da Vinci franchise in seven countries to 2031, with 142 robots generating 375 million złoty a year of instruments and service
Greatest threatIntuitive's discretion: it supplies 72,6% of purchases and bought back three other distributors for $533 million in March 2026
Key metricIntuitive's share of group revenue (44,9%)
Verdict: Synektik is a first-rate distributor that turned a reimbursement decision into a six-fold rise in recurring revenue, and it owns a small, profitable tracer business on the side. But nearly half the company is Intuitive's product under a contract that ends in 2031, and the supplier has just shown it will pay to take territories back. At about 17 times continuing earnings the shares price the franchise as if it were permanent.
📈 SNT valuation, revenue & earnings — P/E, P/S, revenue, EPS →

Synektik is a Warsaw company that sells other people's medical technology to hospitals, and makes one product of its own. Its business is best understood as two things of very different size. The first is distribution: it sells and services Intuitive Surgical's da Vinci surgical robots under an exclusive contract covering Poland, Czechia, Slovakia, Lithuania, Latvia, Estonia and Ukraine12, alongside equipment from Carl Zeiss, Hologic, HistoSonics, Insightec and others3. The second is manufacturing: three of Poland's nine cyclotrons, producing the tracers used in PET scans4.

Segment revenue, year to Sep 2025 (zł m)Medical Equipment and IT — 92%Radiopharmaceuticals — 8%Including intersegment sales; Synektik audited consolidated statements
Almost all of it is distribution.

The numbers. In the year to September 2025 group revenue was 681,6 million złoty, operating profit from continuing operations 157,4 million złoty and continuing net profit 126,0 million złoty, 14,78 złoty a share5. The medical equipment and IT segment had revenue of 631,9 million złoty and the radiopharmaceutical segment 52,9 million złoty6. Intuitive's products were 44,9% of group revenue7. Revenue was 134,8 million złoty six years earlier8.

How it makes money. A robot is sold once, through a public tender; 85,5% of revenue came from tenders9. What follows is the business: instruments, accessories and service, 374,7 million złoty in the twelve months to June 202610, from 142 robots under Synektik's service11. Polish surgeons performed 19,8 thousand da Vinci operations in the year to September 202512, paid for mostly by the National Health Fund since it began reimbursing robotic prostatectomy in April 202213.

In March 2026 Synektik gave away its most speculative project. The cardiotracer research unit was demerged into Syn2bio S.A. and its shares handed to Synektik's holders14, which is why reported profit for the nine months to June 2026 includes a 261,3 million złoty gain15. The business that remains earned 138,0 million złoty of continuing profit in those nine months, against 85,7 million złoty a year earlier16.

The shares were 352,60 złoty on 24 September 2026, a market value of about 3,0 billion złoty1718, about 16,9 times continuing earnings19. Melhus Company, through which chief executive Cezary Kozanecki holds his shares, owns 24,00%20.

The company is older than its growth. It was founded as a limited company on 4 October 2001 and became a joint-stock company on 4 February 201121; its market value in August 2011, in its early days on the stock exchange, was 46,76 million złoty22. For most of the following decade it was a small distributor of imaging equipment and a radiopharmaceutical producer, with revenue of 134,8 million złoty in the year to September 2019 and 125,4 million złoty a year later2324. The da Vinci contract of July 201825 and the reimbursement decision of April 202226 changed its scale: revenue was 446,9 million złoty in the year to September 2023, 168% more than a year earlier27, and 733,4 million złoty in the first nine months of the current year alone28. The company's factsheet puts its five-year revenue growth at 55% a year29. Public money did the rest: management lists investment in medical equipment by the public health sector, funded from the European Union's 2021-2027 budget and the National Recovery Plan, among the main drivers of its sales30.

The moat is narrow, and most of it is borrowed. Synektik is an excellent distributor with an exclusive right that runs to 31 December 203131, in the same year its supplier paid about $533,1 million to take three other territories direct32. The number that would falsify the thesis is Intuitive's share of revenue, 44,9%: if the next annex extends the contract again, Synektik is a durable franchise; if it does not, half the company has a date on it.

The number that tests this moat
Reported
Revenue, and where it comes from
681,6m zł in the year to Sep 2025; 933m zł trailing twelve months to June 2026

About 93% from medical equipment and IT, 44,9% from Intuitive's products; recurring instruments and service 374,7m zł a year.

Source: Synektik audited consolidated financial statements, year to September 2025 ↗
Moat scorecardHow ratings work →
Switching costs7/10
Network effects2/10
Pricing power5/10
Hard to replicate5/10
Disruption resistance5/10
Overall durability5/10

Switching costs score highest: a hospital with a da Vinci and trained surgeons must buy instruments and service from Synektik. Network effects are minimal. Pricing power is moderate because almost everything is sold through public tenders. Replication and disruption resistance are middling because the core asset is a contract Intuitive can decline to renew, and rival robots have entered on financing terms. The radiopharmaceutical business is a small, genuinely owned moat. Durability sits at the bottom of the narrow band.

Dig deeper
DIG DEEPER 01
The Revenue Lines
Synektik is a robot distributor with a small tracer factory attached; the factory is a twelfth of the revenue.
DIG DEEPER 02
The Moat
Synektik earns a 46% return on equity from an exclusive contract it does not own and three cyclotrons it does.
DIG DEEPER 03
Competitors
Synektik's most dangerous competitor is the company that supplies it, and the others are mostly fighting over growth.
DIG DEEPER 04
Major Clients
Synektik has 800 customers and none that matters alone, but most of them answer to the same public payer.
✦ Future bets — beyond today's moat
✦ FUTURE BET 01
The Future Bets
Synektik gave its research bet to shareholders and is betting on taking the da Vinci model to Ukraine and the Baltic states.
⚠ Threats to the moat
⚠ THREAT 01
Nearly Half the Company Is Someone Else's Product
Almost half of Synektik's revenue is a product it may sell only until 2031, at its supplier's discretion.
⚠ THREAT 02
Public Money Sets the Pace
Synektik's growth was switched on by a reimbursement decision, and only another one will keep it running at this pace.
◆ What the market may be missing
◆ THE VARIANT VIEW
What the Market Isn't Pricing In
Synektik's price treats a licence that ends in 2031 as permanent, and Intuitive has just shown what it pays when it takes a territory back.
◆ THE VARIANT VIEW
Inside the Latest Quarter (April-June 2026)
Synektik's record quarter came from robot deliveries; the backlog behind it is less than a sixth of the quarter's sales.
References
  1. ReportedThe first is distribution: it sells and services Intuitive Surgical's da Vinci surgical robots under an exclusive contract covering Poland, Czechia, Slovakia, Lithuania, Latvia, Estonia and Ukraine, alongside equipment from Carl Zeiss, Hologic, HistoSonics, Insightec and others.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  2. ReportedThe first is distribution: it sells and services Intuitive Surgical's da Vinci surgical robots under an exclusive contract covering Poland, Czechia, Slovakia, Lithuania, Latvia, Estonia and Ukraine, alongside equipment from Carl Zeiss, Hologic, HistoSonics, Insightec and others.
    Synektik interim financial statements for 1 October - 31 December 2025 - including the annex extending the da Vinci distribution agreement to 31 December 2031 and adding Ukraine, and the 10,75 złoty dividend. — October - December 2025 · publ. February 2026 · source ↗
  3. ReportedThe first is distribution: it sells and services Intuitive Surgical's da Vinci surgical robots under an exclusive contract covering Poland, Czechia, Slovakia, Lithuania, Latvia, Estonia and Ukraine, alongside equipment from Carl Zeiss, Hologic, HistoSonics, Insightec and others.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  4. ReportedThe second is manufacturing: three of Poland's nine cyclotrons, producing the tracers used in PET scans.
    Synektik annual management board report for the fiscal year to 30 September 2025 - description of the markets: robotic surgery in Poland, PET scanners, cyclotrons and NFZ-funded PET studies. — October 2024 - September 2025 · publ. December 2025 · source ↗
  5. ReportedIn the year to September 2025 group revenue was 681,6 million złoty, operating profit from continuing operations 157,4 million złoty and continuing net profit 126,0 million złoty, 14,78 złoty a share.
    Synektik Group audited consolidated financial statements for the fiscal year to 30 September 2025 (ESEF package) - revenue, costs, continuing and discontinued profit, earnings per share, segment note, cash flow. — October 2024 - September 2025 · publ. December 2025 · source ↗
  6. ReportedThe medical equipment and IT segment had revenue of 631,9 million złoty and the radiopharmaceutical segment 52,9 million złoty.
    Synektik Group audited consolidated financial statements for the fiscal year to 30 September 2025 (ESEF package) - revenue, costs, continuing and discontinued profit, earnings per share, segment note, cash flow. — October 2024 - September 2025 · publ. December 2025 · source ↗
  7. ReportedIntuitive's products were 44,9% of group revenue.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  8. ReportedRevenue was 134,8 million złoty six years earlier.
    Synektik condensed consolidated interim report for 1 October 2018 - 30 September 2019, with the 21 months to September 2018 as comparative - revenue, net profit and segments. — October 2018 - September 2019 · publ. November 2019 · source ↗
  9. ReportedA robot is sold once, through a public tender; 85,5% of revenue came from tenders.
    Synektik annual management board report for the fiscal year to 30 September 2025 - risk factors, customers and suppliers (Intuitive's share of revenue and purchases, public procurement, Affidea, seasonality). — October 2024 - September 2025 · publ. December 2025 · source ↗
  10. ReportedWhat follows is the business: instruments, accessories and service, 374,7 million złoty in the twelve months to June 2026, from 142 robots under Synektik's service.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  11. ReportedWhat follows is the business: instruments, accessories and service, 374,7 million złoty in the twelve months to June 2026, from 142 robots under Synektik's service.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  12. ReportedPolish surgeons performed 19,8 thousand da Vinci operations in the year to September 2025, paid for mostly by the National Health Fund since it began reimbursing robotic prostatectomy in April 2022.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  13. ReportedPolish surgeons performed 19,8 thousand da Vinci operations in the year to September 2025, paid for mostly by the National Health Fund since it began reimbursing robotic prostatectomy in April 2022.
    Synektik interim report for the fiscal year to 30 September 2022 - revenue, segments, installed base in Poland, Czechia and Slovakia, the first dedicated reimbursement and example tenders. — October 2021 - September 2022 · publ. November 2022 · source ↗
  14. ReportedThe cardiotracer research unit was demerged into Syn2bio S.A. and its shares handed to Synektik's holders, which is why reported profit for the nine months to June 2026 includes a 261,3 million złoty gain.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - the demerger of Syn2bio, shareholders and group structure. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  15. ReportedThe cardiotracer research unit was demerged into Syn2bio S.A. and its shares handed to Synektik's holders, which is why reported profit for the nine months to June 2026 includes a 261,3 million złoty gain.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - the demerger of Syn2bio, shareholders and group structure. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  16. ReportedThe business that remains earned 138,0 million złoty of continuing profit in those nine months, against 85,7 million złoty a year earlier.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  17. ReportedThe shares were 352,60 złoty on 24 September 2026, a market value of about 3,0 billion złoty, about 16,9 times continuing earnings.
    Synektik (WSE: SNT) market data - share price 352,60 złoty on 24 September 2026, 52-week range, analysts' rating and target. — September 2026 · publ. 24 September 2026 · source ↗
  18. ReportedThe shares were 352,60 złoty on 24 September 2026, a market value of about 3,0 billion złoty, about 16,9 times continuing earnings.
    Biznesradar, Synektik market-value ratios - market capitalisation 3 007 370 971 złoty at 352,60 złoty. — September 2026 · publ. 24 September 2026 · source ↗
  19. Moat Explorer calcThe shares were 352,60 złoty on 24 September 2026, a market value of about 3,0 billion złoty, about 16,9 times continuing earnings.
    Moat Explorer calculation from Synektik's reported figures (thousands of złoty unless stated). Market value: 352,60 złoty x 8 529 129 shares = 3 007,4 million złoty (about 3,0 billion złoty); at the NBP rate of 3,8570 = $779,7 million (about $780 million). Trailing revenue to June 2026: 681 598,6 - 482 060,1 + 733 427,1 = 932 965,6 (about 933 million złoty). Trailing continuing net profit: 126 019,2 - 85 705,2 + 137 952,7 = 178 266,7; over 8 529 129 shares = 20,90 złoty; P/E 352,60 / 20,90 = 16,9. Equipment and IT segment EBITDA over segment revenue: 187 190,7 / 631 915,5 = 29,6% (FY2025); 143 577,5 / 579 299,1 = 24,8% (FY2024); 98 943,8 / 410 834,1 = 24,1% (FY2023); 29 865,3 / 139 272,7 = 21,4% (FY2022); 18 636,4 / 100 878,6 = 18,5% (FY2021); 19 605,9 / 112 126,1 = 17,5% (FY2019). Radiopharmaceutical segment EBITDA margin: 16 061,3 / 52 937,4 = 30,3% (FY2025); 16 276,6 / 46 615,7 = 34,9% (FY2024). Recurring revenue, trailing: 374,7 / 59,8 = 6,3 times (September 2022 to June 2026); installed base 142 / 37 = 3,8 times. Recurring revenue per year-end robot: 311,3 / 113 = 2,75 million złoty (FY2025); 193,9 / 86 = 2,25 million złoty (FY2024). Procedures per year-end robot, FY2025: Poland 19 800 / 75 = 264; Czechia and Slovakia 12 500 / 38 = 329. Revenue per average employee: 681,6 / 221 = 3,08 million złoty. Export share: 183,7 / 681,6 = 27,0%. Equipment segment share of revenue excluding intragroup sales: 631,1 / 681,6 = 92,6% (about 93%). Intuitive products: 44,9% x 681,6 = 306,0 million złoty; other equipment, IT and service 681,6 - 306,0 - 50,5 = 325,1 million złoty. Synektik market value over the Estonian contract: 3 007,4 / 41 = 73 (roughly seventy). Dividend paid February 2026: 10,75 x 8 529 129 = 91,7 million złoty; dividend per share 10,75 / 0,45 = 23,9 times since 2021. Free cash flow: FY2025 78,3 - 17,4 = 60,9 million złoty; FY2024 89,6 - 44,9 = 44,7 million złoty. IT4KAN price over market value: 4,15 / 3 007,4 = 0,14%. Recurring revenue, April-June 2025: 103,6 / 1,26 = 82,2 million złoty. Backlog plus active offers at June 2026: 44,2 + 160,8 = 205,0 million złoty. NFZ spending per robotic operation: 59 / 2,1 = 28 thousand złoty (2022); 167 / 5,4 = 31 thousand złoty (2023); 300 / 11 = 27 thousand złoty (2024). NFZ-funded PET studies: 96,1 / 89,3 - 1 = 7,6% (about 8%); per scanner 96 100 / 37 = about 2 600. Affidea: 29,0% x 52,9 = 15,3 million złoty, against segment EBITDA of 16,1 million złoty. Synektik's installed base as a share of Intuitive's: 142 / 11 710 = 1,2%. Czech and Slovak installed base: 42 / 16 = 2,6 times. Equipment segment purchases from others: 100 - 80,2 - 6,8 = 13,0%. Years of exclusivity from September 2026 to 31 December 2031: about 5,3. Year-end P/E and P/S (market value at 30 September over net profit and revenue; continuing profit from FY2024): 122,8 / 9,136 = 13,4 and 122,8 / 134,8 = 0,91 (FY2019); 190,2 / 8,811 = 21,6 and 1,52 (FY2020); 252,5 / 8,384 = 30,1 and 1,96 (FY2021); 237,5 / 10,709 = 22,2 and 1,42 (FY2022); 516,9 / 52,452 = 9,9 and 1,16 (FY2023); 1 635,9 / 98,909 = 16,5 and 2,62 (FY2024); 2 149,3 / 126,019 = 17,1 and 3,15 (FY2025); market values from closing prices of 14,40 złoty, 22,30, 29,60, 27,85, 60,60, 191,80 and 252,00 x 8 529 129. — October 2018 - June 2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in Synektik's financial statements, management board reports, factsheet and market data; operands shown in the source line.
  20. ReportedMelhus Company, through which chief executive Cezary Kozanecki holds his shares, owns 24,00%.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - the demerger of Syn2bio, shareholders and group structure. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  21. ReportedIt was founded as a limited company on 4 October 2001 and became a joint-stock company on 4 February 2011; its market value in August 2011, in its early days on the stock exchange, was 46,76 million złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  22. ReportedIt was founded as a limited company on 4 October 2001 and became a joint-stock company on 4 February 2011; its market value in August 2011, in its early days on the stock exchange, was 46,76 million złoty.
    Synektik market capitalisation history - from 46,76 million złoty in August 2011 to about 3 billion złoty. — 2011-2026 · publ. September 2026 · source ↗
  23. ReportedFor most of the following decade it was a small distributor of imaging equipment and a radiopharmaceutical producer, with revenue of 134,8 million złoty in the year to September 2019 and 125,4 million złoty a year later.
    Synektik condensed consolidated interim report for 1 October 2018 - 30 September 2019, with the 21 months to September 2018 as comparative - revenue, net profit and segments. — October 2018 - September 2019 · publ. November 2019 · source ↗
  24. ReportedFor most of the following decade it was a small distributor of imaging equipment and a radiopharmaceutical producer, with revenue of 134,8 million złoty in the year to September 2019 and 125,4 million złoty a year later.
    Synektik Group interim report for the fiscal year to 30 September 2020 - revenue, net profit, earnings per share and dividends. — October 2019 - September 2020 · publ. November 2020 · source ↗
  25. ReportedThe da Vinci contract of July 2018 and the reimbursement decision of April 2022 changed its scale: revenue was 446,9 million złoty in the year to September 2023, 168% more than a year earlier, and 733,4 million złoty in the first nine months of the current year alone.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  26. ReportedThe da Vinci contract of July 2018 and the reimbursement decision of April 2022 changed its scale: revenue was 446,9 million złoty in the year to September 2023, 168% more than a year earlier, and 733,4 million złoty in the first nine months of the current year alone.
    Synektik interim report for the fiscal year to 30 September 2022 - revenue, segments, installed base in Poland, Czechia and Slovakia, the first dedicated reimbursement and example tenders. — October 2021 - September 2022 · publ. November 2022 · source ↗
  27. ReportedThe da Vinci contract of July 2018 and the reimbursement decision of April 2022 changed its scale: revenue was 446,9 million złoty in the year to September 2023, 168% more than a year earlier, and 733,4 million złoty in the first nine months of the current year alone.
    Synektik quarterly report for the fourth quarter of the fiscal year to 30 September 2023 - revenue up 168%, order intake, recurring revenue, installed base and procedures. — October 2022 - September 2023 · publ. November 2023 · source ↗
  28. ReportedThe da Vinci contract of July 2018 and the reimbursement decision of April 2022 changed its scale: revenue was 446,9 million złoty in the year to September 2023, 168% more than a year earlier, and 733,4 million złoty in the first nine months of the current year alone.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  29. ReportedThe company's factsheet puts its five-year revenue growth at 55% a year.
    Synektik factsheet for the third quarter of the 2025 fiscal year - revenue by quarter, the split between contract equipment sales and recurring revenue, Poland against abroad, market value, P/E and free float at 31 July 2026. — Quarter to June 2026 · publ. August 2026 · source ↗
  30. ReportedPublic money did the rest: management lists investment in medical equipment by the public health sector, funded from the European Union's 2021-2027 budget and the National Recovery Plan, among the main drivers of its sales.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  31. ReportedSynektik is an excellent distributor with an exclusive right that runs to 31 December 2031, in the same year its supplier paid about $533,1 million to take three other territories direct.
    Synektik interim financial statements for 1 October - 31 December 2025 - including the annex extending the da Vinci distribution agreement to 31 December 2031 and adding Ukraine, and the 10,75 złoty dividend. — October - December 2025 · publ. February 2026 · source ↗
  32. ReportedSynektik is an excellent distributor with an exclusive right that runs to 31 December 2031, in the same year its supplier paid about $533,1 million to take three other territories direct.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11 710 da Vinci systems up 12%; the 1 March 2026 acquisition of the da Vinci and Ion distribution businesses of ab medica, Abex and Excelencia Robótica for approximately $533,1 million in cash, with $279,8 million of intangible and other assets and $218,0 million of goodwill, making Intuitive the direct distributor in Italy, Spain and Portugal). Same document as Intuitive's own _IS_Q226 record. — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
Sources
Generated September 24, 2026